Consequently, targeting glutamine metabolism combined with PD-1/PD-L1 checkpoint blockade therapy and/or chemotherapy could represent a potentially effective therapeutic strategy for improving treatment outcomes among bladder cancer patients. This evidence concerns the gene PDCD1 and urinary bladder carcinoma.